Détail d'une personne de l'annuaire - fr | Cancéropôle Est, la recherche innovante dans la lutte contre le cancer

Prognostic stratification ability of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy.

Roussot N, Constantin G, Desmoulins I, Bergeron A, Arnould L, Beltjens F, Mayeur D, Kaderbhai C, Hennequin A, Jankowski C, Padeano MM, Costaz H, Jacinto S, Michel E, Amet A, Coutant C, Costa B, Jouannaud C, Deblock M, Levy C, Ferrero JM, Kerbrat P, Brain E, Mouret-Reynier MA, Coudert B, Bertaut A, Ladoire S

Eur J Cancer. 2024 03 26;202:114037

Pathologic and immunohistochemical prognostic markers in residual triple-negative breast cancer after neoadjuvant chemotherapy.

Ilie SM, Briot N, Constatin G, Ilie A, Beltjens F, Ladoire S, Desmoulins I, Hennequin A, Bertaut A, Coutant C, Causeret S, Ghozali N, Coudert B, Arnould L

Front Oncol. 2024 01 10;13:1309890

Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy.

Ilie SM, Briot N, Constantin G, Roussot N, Ilie A, Bergeron A, Arnould L, Beltjens F, Desmoulin I, Mayeur D, Kaderbhai C, Hennequin A, Jankowski C, Padeano MM, Costaz H, Amet A, Coutant C, Coudert B, Bertaut A, Ladoire S

Breast Cancer. 2023 08 10;:

Durable response of lung carcinoma patients to EGFR tyrosine kinase inhibitors is determined by germline polymorphisms in some immune-related genes.

Dalens L, Niogret J, Richard C, Chevrier S, Foucher P, Coudert B, Lagrange A, Favier L, Westeel V, Kim S, Adotevi O, Chapusot C, Martin L, Arnould L, Kaderbhai CG, Boidot R

Mol Cancer. 2023 07 29;22(1):120

Taxane rechallenge during metastatic disease in HER-2 negative breast cancer patients: Clinical activity, tolerance and survival results.

Réda M, Fouquier A, Desmoulins I, Mayeur D, Kaderbhai C, Ilie S, Hennequin A, Coudert B, Bertaut A, Ladoire S

Breast. 2023 02 4;68:149-156

Parallel evolution and differences in seroprevalence of SARS-CoV-2 antibody between patients with cancer and health care workers in a tertiary cancer centre during the first and second wave of COVID-19 pandemic: canSEROcov-II cross-sectional study.

Ladoire S, Rederstorff E, Goussot V, Parnalland S, Briot N, Ballot E, Truntzer C, Ayati S, Bengrine-Lefevre L, Bremaud N, Coudert B, Desmoulins I, Favier L, Fraisse C, Fumet JD, Hennequin A, Hervieu A, Ilie S, Kaderbhai C, Lagrange A, Martin N, Mazilu I, Mayeur D, Palmier R, Simonet-Lamm AL, Vincent J, Zanetta S, Arnould L, Coutant C, Bertaut A, Ghiringhelli F

Eur J Cancer. 2022 Feb 1;165:13-24

MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells.

Limagne E, Nuttin L, Thibaudin M, Jacquin E, Aucagne R, Bon M, Revy S, Barnestein R, Ballot E, Truntzer C, Derangère V, Fumet JD, Latour C, Rébé C, Bellaye PS, Kaderbhaï CG, Spill A, Collin B, Callanan MB, Lagrange A, Favier L, Coudert B, Arnould L, Ladoire S, Routy B, Joubert P, Ghiringhelli F

Cancer Cell. 2022 Jan 17;:

Personalized Reimbursement Model (PRM) program: A real-world data platform of cancer drugs use to improve and personalize drug pricing and reimbursement in France.

Squara PA, Luu VP, Pérol D, Coudert B, Machuron V, Bachot C, Samelson L, Florentin V, Pinguet JM, Ben Hadj Yahia B

PLoS One. 2022 ;17(4):e0267242

IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer.

Molinier O, Besse B, Barlesi F, Audigier-Valette C, Friard S, Monnet I, Jeannin G, Mazières J, Cadranel J, Hureaux J, Hilgers W, Quoix E, Coudert B, Moro-Sibilot D, Fauchon E, Westeel V, Brun P, Langlais A, Morin F, Souquet PJ, Girard N

ESMO Open. 2021 Dec 22;7(1):100353

Treatment strategies for unresectable locally advanced non-small cell lung cancer in the real-life ESME cohort.

Girard N, Perol M, Simon G, Audigier Valette C, Gervais R, Debieuvre D, Schott R, Quantin X, Coudert B, Lena H, Carton M, Robain M, Filleron T, Chouaid C

Lung Cancer. 2021 Nov 6;162:119-127

Does large NGS panel analysed using exome tumour sequencing improve the management of advanced non-small-cell lung cancers?

Niogret J, Dalens L, Truntzer C, Chevrier S, Favier L, Lagrange A, Coudert B, Fraisse C, Foucher P, Zouak A, Westeel V, Goussot V, Dérangère V, Albuisson J, Arnould L, Boidot R, Kaderbhai CG, Ghiringhelli F

Lung Cancer. 2021 Aug 29;161:98-107

Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME).

Dano D, Lardy-Cleaud A, Monneur A, Quenel-Tueux N, Levy C, Mouret-Reynier MA, Coudert B, Mailliez A, Ferrero JM, Guiu S, Campone M, de La Motte Rouge T, Petit T, Pistilli B, Dalenc F, Simon G, Lerebours F, Chabaud S, Bertucci F, Gonçalves A

ESMO Open. 2021 Jul 22;6(4):100220

Population pharmacokinetics and exposure-response relationship of trastuzumab and bevacizumab in early-stage breast cancer.

Petitcollin A, Azzopardi N, Pierga JY, Ternant D, Navarro-Teulon I, Desvignes C, Mouret-Reynier MA, Coudert B, Paintaud G

Eur J Clin Pharmacol. 2021 Jul 10;:

Seroprevalence of SARS-CoV-2 among the staff and patients of a French cancer centre after first lockdown: The canSEROcov study.

Ladoire S, Goussot V, Redersdorff E, Cueff A, Ballot E, Truntzer C, Ayati S, Bengrine-Lefevre L, Bremaud N, Coudert B, Desmoulins I, Favier L, Fraisse C, Fumet JD, Hanu R, Hennequin A, Hervieu A, Ilie S, Kaderbhai C, Lagrange A, Martin N, Mazilu I, Mayeur D, Palmier R, Simonet-Lamm AL, Vincent J, Zanetta S, Arnould L, Coutant C, Bertaut A, Ghiringhelli F

Eur J Cancer. 2021 Feb 27;148:359-370

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.

Borghaei H, Gettinger S, Vokes EE, Chow LQM, Burgio MA, de Castro Carpeno J, Pluzanski A, Arrieta O, Frontera OA, Chiari R, Butts C, Wójcik-Tomaszewska J, Coudert B, Garassino MC, Ready N, Felip E, García MA, Waterhouse D, Domine M, Barlesi F, Antonia S, Wohlleber M, Gerber DE, Czyzewicz G, Spigel DR, Crino L, Eberhardt WEE, Li A, Marimuthu S, Brahmer J

J Clin Oncol. 2021 Jan 15;:JCO2001605

Evolution in the real-world therapeutic strategies in more than 20,000 women with breast cancer having received human epidermal growth factor receptor 2-targeted treatments: Results from the french personalized reimbursement model database (2011-2018).

Cottu P, Coudert B, Perol D, Doly A, Manson J, Aujoulat O, Barletta H, Chalabi N, Samelson L, Pivot X

Eur J Cancer. 2020 Nov 8;141:209-217

Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher study.

Coudert B, Pierga JY, Mouret-Reynier MA, Kerrou K, Ferrero JM, Petit T, Du FL, Dupré PF, Bachelot T, Gabelle P, Chauvet MP, Coeffic D, Barbe C, Prevost JB, Paintaud G, Thibault G, Ferhat A, Dupin J, Berriolo-Riedinger A, Arnould L

EClinicalMedicine. 2020 Nov;28:100566

[Multidisciplinary team meeting in supportive care: 12 years of experience in a French comprehensive cancer center].

Favier L, Bremaud N, Tharin Z, Blanc J, Bertaut A, Alavoine V, Dubief A, Truc G, Dorlean C, Coudert B

Bull Cancer. 2020 Sep 21;:

Lack of everolimus diffusion in pleural fluid during pleural progression of breast cancer: A case report.

Vaury C, Macaire P, Goirand F, Coudert B, Guérard P, Schmitt A

J Oncol Pharm Pract. 2020 Jun 3;:1078155220927771

Outcomes of concurrent radiotherapy with weekly docetaxel and platinum-based chemotherapy in stage III non-small-cell lung cancer.

Kaderbhaï CG, Coudert B, Bertaut A, Adnet J, Favier L, Lagrange A, Peignaux-Casasnovas K, Mettey L, Tharin Z, Foucher P, Martin E

Cancer Radiother. 2020 May 18;:

Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME metastatic breast cancer cohort.

Frank S, Carton M, Dubot C, Campone M, Pistilli B, Dalenc F, Mailliez A, Levy C, D'Hondt V, Debled M, Vermeulin T, Coudert B, Perrin C, Gonçalves A, Uwer L, Ferrero JM, Eymard JC, Petit T, Mouret-Reynier MA, Patsouris A, Guesmia T, Bachelot T, Robain M, Cottu P

Breast. 2020 Apr 23;52:50-57

[Prediction performances of F-FDG PET and CGFL/Curie nomogram after preoperative chemotherapy in Breast cancer].

Vincent L, Jankowski C, Arnould L, Coudert B, Rouzier R, Reyal F, Humbert O, Coutant C

Gynecol Obstet Fertil Senol. 2020 Mar 20;:

A decrease in brown adipose tissue activity is associated with weight gain during chemotherapy in early breast cancer patients.

Ginzac A, Barres B, Chanchou M, Gadéa E, Molnar I, Merlin C, Coudert B, Thivat E, Durando X

BMC Cancer. 2020 Feb 4;20(1):96

Somatic profile in lung cancers is associated to reproductive factors in never-smokers women: Results from the IFCT-1002 BioCAST study.

Fontaine-Delaruelle C, Mazières J, Cadranel J, Mastroianni B, Dubos-Arvis C, Dumont P, Monnet I, Pichon E, Locatelli-Sanchez M, Dixmier A, Coudert B, Fraboulet S, Foucher P, Dansin E, Baize N, Vincent M, Missy P, Morin F, Moro-Sibilot D, Couraud S,

Respir Med Res. 2020 Jan 31;77:58-66

Management and outcome of male metastatic breast cancer in the national multicenter observational research program Epidemiological Strategy and Medical Economics (ESME).

Sirieix J, Fraisse J, Mathoulin-Pelissier S, Leheurteur M, Vanlemmens L, Jouannaud C, Diéras V, Lévy C, Ung M, Mouret-Reynier MA, Petit T, Coudert B, Brain E, Pistilli B, Ferrero JM, Goncalves A, Uwer L, Patsouris A, Tredan O, Courtinard C, Gourgou S, Frénel JS

Ther Adv Med Oncol. 2020 ;12:1758835920980548

Monitoring HSP70 exosomes in cancer patients' follow up: a clinical prospective pilot study.

Chanteloup G, Cordonnier M, Isambert N, Bertaut A, Hervieu A, Hennequin A, Luu M, Zanetta S, Coudert B, Bengrine L, Desmoulins I, Favier L, Lagrange A, Pages PB, Gutierrez I, Lherminier J, Avoscan L, Jankowski C, Rébé C, Chevriaux A, Padeano MM, Coutant C, Ladoire S, Causeret S, Arnould L, Charon-Barra C, Cottet V, Blanc J, Binquet C, Bardou M, Garrido C, Gobbo J

J Extracell Vesicles. 2020 ;9(1):1766192

Visceral osteopathic manipulative treatment reduces patient reported digestive toxicities induced by adjuvant chemotherapy in breast cancer: A randomized controlled clinical study.

Lagrange A, Decoux D, Briot N, Hennequin A, Coudert B, Desmoulins I, Bertaut A

Eur. J. Obstet. Gynecol. Reprod. Biol.. 2019 Aug 12;241:49-55

Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics.

Diéras V, Bonnefoi H, Alba E, Awada A, Coudert B, Pivot X, Gligorov J, Jager A, Zambelli S, Lindeman GJ, Charpentier E, Emmons GT, Garcia-Ribas I, Paridaens R, Verweij J

Breast Cancer Res. Treat.. 2019 Jun 6;:

Real-world treatment patterns, clinical practice and outcomes for locally advanced, non resectable, non-small cell lung cancer from the French ESME Lung database.

Girard N, Pérol M, Simon G, Audigier Valette C, Gervais R, Debieuvre D, Schott R, Quantin X, Coudert B, Lena H, Carton M, Robain M, Filleron T, Chouaid C

Ann. Oncol.. 2019 Apr;30 Suppl 2:ii34

Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients.

Limagne E, Richard C, Thibaudin M, Fumet JD, Truntzer C, Lagrange A, Favier L, Coudert B, Ghiringhelli F

Oncoimmunology. 2019 ;8(4):e1564505

Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy.

Fumet JD, Richard C, Ledys F, Klopfenstein Q, Joubert P, Routy B, Truntzer C, Gagné A, Hamel MA, Guimaraes CF, Coudert B, Arnould L, Favier L, Lagrange A, Ladoire S, Saintigny P, Ortiz-Cuaran S, Perol M, Foucher P, Hofman P, Ilie M, Chevrier S, Boidot R, Derangere V, Ghiringhelli F

Br. J. Cancer. 2018 Oct 15;:

Exome analysis reveals genomic markers associated with better efficacy of nivolumab in lung cancer patients.

Richard C, Fumet JD, Chevrier S, Derangère V, Ledys F, Lagrange A, Favier L, Coudert B, Arnould L, Truntzer C, Boidot R, Ghiringhelli F

Clin. Cancer Res.. 2018 Aug 28;:

Primary Resistance to Afatinib in a Patient with Lung Adenocarcinoma Harboring Uncommon EGFR Mutations: S768I and V769L.

Niogret J, Coudert B, Boidot R

J Thorac Oncol. 2018 Jul;13(7):e113

Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases.

Vokes EE, Ready N, Felip E, Horn L, Burgio MA, Antonia SJ, Arén Frontera O, Gettinger S, Holgado E, Spigel D, Waterhouse D, Domine M, Garassino M, Chow LQM, Blumenschein G, Barlesi F, Coudert B, Gainor J, Arrieta O, Brahmer J, Butts C, Steins M, Geese WJ, Li A, Healey D, Crinò L

Ann. Oncol.. 2018 Apr 1;29(4):959-965

Association between lung cancer somatic mutations and occupational exposure in never-smokers.

Paris C, Do P, Mastroianni B, Dixmier A, Dumont P, Pichon E, Chouaid C, Coudert B, Foucher P, Fraboulet S, Locatelli-Sanchez M, Baize N, Dansin E, Moreau L, Vincent M, Missy P, Morin F, Moro-Sibilot D, Couraud S, ,

Eur. Respir. J.. 2017 Oct;50(4):

Antibiotic Use Does Not Appear to Influence Response to Nivolumab.

Kaderbhai C, Richard C, Fumet JD, Aarnink A, Foucher P, Coudert B, Favier L, Lagrange A, Limagne E, Boidot R, Ghiringhelli F

Anticancer Res.. 2017 06;37(6):3195-3200

[The anti-tumor immune response in breast cancer: Update and therapeutic perspectives].

Ladoire S, Derangère V, Arnould L, Thibaudin M, Coudert B, Lorgis V, Desmoulins I, Chaix M, Fumoleau P, Ghiringhelli F

Ann Pathol. 2017 Feb;37(1):133-141

Predictive factors of pathologic complete response of HER2-positive breast cancer after preoperative chemotherapy with trastuzumab: development of a specific predictor and study of its utilities using decision curve analysis.

Jankowski C, Guiu S, Cortet M, Charon-Barra C, Desmoulins I, Lorgis V, Arnould L, Fumoleau P, Coudert B, Rouzier R, Coutant C, Reyal F

Breast Cancer Res. Treat.. 2017 Jan;161(1):73-81

Response to first line chemotherapy regimen is associated with efficacy of nivolumab in non-small-cell lung cancer.

Kaderbhai CG, Richard C, Fumet JD, Aarnink A, Ortiz-Cuaran S, Pérol M, Foucher P, Coudert B, Favier L, Lagrange A, Limagne E, Boidot R, Ladoire S, Poudenx M, Ilie M, Hofman P, Saintigny P, Ghiringhelli F

Oncoimmunology. 2017 ;6(9):e1339856

[Breast cancer screening: On our way to the future].

Delaloge S, Bachelot T, Bidard FC, Espie M, Brain E, Bonnefoi H, Gligorov J, Dalenc F, Hardy-Bessard AC, Azria D, Jacquin JP, Lemonnier J, Jacot W, Goncalves A, Coutant C, Ganem G, Petit T, Penault-Lorca F, Debled M, Campone M, Levy C, Coudert B, Lortholary A, Venat-Bouvet L, Grenier J, Bourgeois H, Asselain B, Arvis J, Castro M, Tardivon A, Cox DG, Arveux P, Balleyguier C, André F, Rouzier R,

Bull Cancer. 2016 Sep;103(9):753-63

Use of dedicated gene panel sequencing using next generation sequencing to improve the personalized care of lung cancer.

Kaderbhai CG, Boidot R, Beltjens F, Chevrier S, Arnould L, Favier L, Lagrange A, Coudert B, Ghiringhelli F

Oncotarget. 2016 Apr;7(17):24860-70

HER2-positivity rates in breast cancer: no variation over time when clinicopathological features and testing are stable.

Beltjens F, Bertaut A, Pigeonnat S, Loustalot C, Desmoulins I, Charon-Barra C, Coudert B, Fumoleau P, Arveux P, Arnould L

Eur J Cancer Care (Engl). 2015 Oct 27

Transcriptional expression of 8 genes predicts pathological response to first-line docetaxel + trastuzumab-based neoadjuvant chemotherapy.

Schmitt E, Vegran F, Chevrier S, Burillier L, Cadouot M, Lizard-Nacol S, Coudert B, Fumoleau P, Arnould L, Boidot R

BMC Cancer. 2015 Mar 24;15(1):169.

BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers.

Couraud S, Souquet PJ, Paris C, Do P, Doubre H, Pichon E, Dixmier A, Monnet I, Etienne-Mastroianni B, Vincent M, Tredaniel J, Perrichon M, Foucher P, Coudert B, Moro-Sibilot D, Dansin E, Labonne S, Missy P, Morin F, Blanche H, Zalcman G

Eur Respir J. 2015 Feb 5. pii: ERJ-00972-2014.

Ixabepilone alone or with cetuximab as first-line treatment for advanced/metastatic triple-negative breast cancer.

Tredan O, Campone M, Jassem J, Vyzula R, Coudert B, Pacilio C, Prausova J, Hardy-Bessard AC, Arance A, Mukhopadhyay P, Aloe A, Roche H

Clin Breast Cancer. 2015 Feb;15(1):8-15

Role of positron emission tomography for the monitoring of response to therapy in breast cancer.

Humbert O, Cochet A, Coudert B, Berriolo-Riedinger A, Kanoun S, Brunotte F, Fumoleau P

Oncologist. 2015 Feb;20(2):94-104

Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER):

Coudert B, Pierga JY, Mouret-Reynier MA, Kerrou K, Ferrero JM, Petit T, Kerbrat P, Dupre PF, Bachelot T, Gabelle P, Giard S, Coeffic D, Bougnoux P, Prevost JB, Paintaud G, Thibault G, Hernandez J, Coudert M, Arnould L, Berriolo-Riedinger A

Lancet Oncol. 2014 Dec;15(13):1493-502

Next-generation sequencing analysis of lung and colon carcinomas reveals a variety of genetic alterations.

Chevrier S, Arnould L, Ghiringhelli F, Coudert B, Fumoleau P, Boidot R

Int J Oncol. 2014 Sep;45(3):1167-74

HER2-positive breast cancer: (1)(8)F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy.

Humbert O, Cochet A, Riedinger JM, Berriolo-Riedinger A, Arnould L, Coudert B, Desmoulins I, Toubeau M, Dygai-Cochet I, Guiu S, Coutant C, Fumoleau P, Brunotte F

Eur J Nucl Med Mol Imaging. 2014 Aug;41(8):1525-33

(1)(8)F-FDG PET/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations.

Cochet A, Dygai-Cochet I, Riedinger JM, Humbert O, Berriolo-Riedinger A, Toubeau M, Guiu S, Coutant C, Coudert B, Fumoleau P, Brunotte F

Eur J Nucl Med Mol Imaging. 2014 Mar;41(3):428-37

Brown adipose tissue activity in relation to weight gain during chemotherapy in breast cancer patients: a pilot study.

Gadea E, Thivat E, Merlin C, Paulon R, Kwiatkowski F, Chadeyras JB, Coudert B, Boirie Y, Morio B, Durando X

Nutr Cancer. 2014;66(7):1092-6

Impact of neoadjuvant chemotherapy on survival in breast cancer patients in daily practice: a population-based study.

Dabakuyo TS, Arnaud A, Maingon P, Causeret S, Coudert B, Fumoleau P, Arnould L, Poillot ML, Arveux P, Crehange G, Bonnetain F

Eur J Cancer Care (Engl). 2013 Sep;22(5):638-47

[Poor prognostic value of weight change during chemotherapy in non-metastatic breast cancer patients: causes, mechanisms involved and preventive strategies].

Gadea E, Thivat E, Wang-Lopez Q, Viala M, Paulon R, Planchat E, Chadeyras JB, Merlin C, Coudert B, Bignon YJ, Morio B, Durando X

Bull Cancer. 2013 Sep;100(9):865-70

Pathological response and survival after neoadjuvant therapy for breast cancer: a 30-year study.

Guiu S, Arnould L, Bonnetain F, Dalban C, Favier L, Desmoulins I, Crehange G, Coutant C, Fumoleau P, Coudert B

Breast. 2013 Jun;22(3):301-8

Albumin-coated monodisperse magnetic poly(glycidyl methacrylate) microspheres with immobilized antibodies: application to the capture of epithelial cancer cells.

Horak D, Svobodova Z, Autebert J, Coudert B, Plichta Z, Kralovec K, Bilkova Z, Viovy JL

J Biomed Mater Res A. 2013 Jan;101(1):23-32

Predictive Factors of Response in HER2-Positive Breast Cancer Treated by Neoadjuvant Therapy.

Guiu S, Mouret Reynier MA, Toure M, Coudert B

J Oncol. 2013;2013:854121

Treatment patterns, clinical outcomes and health care costs associated with HER2-positive breast cancer with central nervous system metastases: a French multicentre observational study.

Baffert S, Cottu P, Kirova YM, Mercier F, Simondi C, Bachelot T, Le Rhun E, Levy C, Gutierrez M, Madranges N, Moldovan C, Coudert B, Spaeth D, Serin D, Cotte FE, Benjamin L, Maillard C, Laulhere-Vigneau S, Durand-Zaleski I

BMC Health Serv Res. 2013 Oct 31;13:456

Prediction of overall survival through circadian rest-activity monitoring during chemotherapy for metastatic colorectal cancer.

Innominato PF, Giacchetti S, Bjarnason GA, Focan C, Garufi C, Coudert B, Iacobelli S, Tampellini M, Durando X, Mormont MC, Waterhouse J, Levi FA

Int J Cancer. 2012 Dec 1;131(11):2684-92

Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer: a meta-analysis.

Giacchetti S, Dugue PA, Innominato PF, Bjarnason GA, Focan C, Garufi C, Tumolo S, Coudert B, Iacobelli S, Smaaland R, Tampellini M, Adam R, Moreau T, Levi F

Ann Oncol. 2012 Dec;23(12):3110-6

Changes in 18F-FDG tumor metabolism after a first course of neoadjuvant chemotherapy in breast cancer: influence of tumor subtypes.

Humbert O, Berriolo-Riedinger A, Riedinger JM, Coudert B, Arnould L, Cochet A, Loustalot C, Fumoleau P, Brunotte F

Ann Oncol. 2012 Oct;23(10):2572-7

Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).

Cadranel J, Mauguen A, Faller M, Zalcman G, Buisine MP, Westeel V, Longchampt E, Wislez M, Coudert B, Daniel C, Chetaille B, Michiels S, Blons H, Solassol J, De Fraipont F, Foucher P, Urban T, Lacroix L, Poulot V, Quoix E, Antoine M, Danton G, Morin F, Chouaid C, Pignon JP

J Thorac Oncol. 2012 Oct;7(10):1490-502.

Neoadjuvant therapy for breast cancer has no benefits on overall survival or on the mastectomy rate in routine clinical practice. A population-based study with a median follow-up of 11 years using propensity score matching.

Le Ray I, Dabakuyo S, Crehange G, Bardou M, Arnould L, Fraisse J, Fumoleau P, Coudert B, Causeret S, Arveux P, Maingon P, Bonnetain F

Eur J Cancer. 2012 Oct;48(15):2300-10

Evaluation of breast tumor blood flow with dynamic first-pass 18F-FDG PET/CT: comparison with angiogenesis markers and prognostic factors.

Cochet A, Pigeonnat S, Khoury B, Vrigneaud JM, Touzery C, Berriolo-Riedinger A, Dygai-Cochet I, Toubeau M, Humbert O, Coudert B, Fumoleau P, Arnould L, Brunotte F

J Nucl Med. 2012 Apr;53(4):512-20

Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy.

Coudert B, Ciuleanu T, Park K, Wu YL, Giaccone G, Brugger W, Gopalakrishna P, Cappuzzo F

Ann Oncol. 2012 Feb;23(2):388-94

Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3.

Borget I, Cadranel J, Pignon JP, Quoix E, Coudert B, Westeel V, Dansin E, Madelaine J, Madroszyk A, Friard S, Daniel C, Morin F, Chouaid C

Eur Respir J. 2012 Jan;39(1):172-9

Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial.

Coudert B, Asselain B, Campone M, Spielmann M, Machiels JP, Penault-Llorca F, Serin D, Levy C, Romieu G, Canon JL, Orfeuvre H, Piot G, Petit T, Jerusalem G, Audhuy B, Veyret C, Beauduin M, Eymard JC, Martin AL, Roche H

Oncologist. 2012;17(7):900-9

Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer.

Cochet A, Quilichini G, Dygai-Cochet I, Touzery C, Toubeau M, Berriolo-Riedinger A, Coudert B, Cottin Y, Fumoleau P, Brunotte F

Breast Cancer Res Treat. 2011 Dec;130(3):845-54

Feasibility and safety of weekly sequential epirubicin-paclitaxel as adjuvant treatment for operable breast cancer patients older than 70 years.

Ladoire S, Rambach L, Quipourt V, Favier L, Ghiringhelli F, Arnould L, Pfitzenmeyer P, Fumoleau P, Coudert B

Clin Breast Cancer. 2011 Aug;11(4):235-40

In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival.

Ladoire S, Mignot G, Dabakuyo S, Arnould L, Apetoh L, Rebe C, Coudert B, Martin F, Bizollon MH, Vanoli A, Coutant C, Fumoleau P, Bonnetain F, Ghiringhelli F

J Pathol. 2011 Jul;224(3):389-400

T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival.

Ladoire S, Arnould L, Mignot G, Apetoh L, Rebe C, Martin F, Fumoleau P, Coudert B, Ghiringhelli F

Br J Cancer. 2011 Jul 26;105(3):366-71

Long-term recurrence of secretory breast carcinoma with metastatic sentinel lymph nodes.

Tixier H, Picard A, Guiu S, Coudert B, Loustalot C, Depret O, Arnould L, Cuisenier J

Arch Gynecol Obstet. 2011 Mar;283 Suppl 1:77-8

Long-term follow-up of HER2-overexpressing stage II or III breast cancer treated by anthracycline-free neoadjuvant chemotherapy.

Guiu S, Liegard M, Favier L, van Praagh I, Largillier R, Weber B, Coeffic D, Moreau L, Priou F, Campone M, Gligorov J, Vanlemmens L, Trillet-Lenoir V, Arnould L, Coudert B

Ann Oncol. 2011 Feb;22(2):321-8

Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy.

Ladoire S, Arnould L, Mignot G, Coudert B, Rebe C, Chalmin F, Vincent J, Bruchard M, Chauffert B, Martin F, Fumoleau P, Ghiringhelli F

Breast Cancer Res Treat. 2011 Jan;125(1):65-72

Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer.

Guiu S, Gauthier M, Coudert B, Bonnetain F, Favier L, Ladoire S, Tixier H, Guiu B, Penault-Llorca F, Ettore F, Fumoleau P, Arnould L

Br J Cancer. 2010 Oct 26;103(9):1335-42.

Spontaneous pyopneumothorax in patients treated with mTOR inhibitors for subpleural pulmonary metastases.

Ladoire S, Beynat C, Diaz P, Coudert B, Favier L, Ghiringhelli F

Med Oncol. 2010 Sep;27(3):938-41

[Management of metastatic HER2-positive breast cancer: present and future]

Guiu S, Coudert B, Favier L, Arnould L, Fumoleau P

Bull Cancer. 2010 Mar;97(3):365-83.

Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial.

Spielmann M, Roche H, Delozier T, Canon JL, Romieu G, Bourgeois H, Extra JM, Serin D, Kerbrat P, Machiels JP, Lortholary A, Orfeuvre H, Campone M, Hardy-Bessard AC, Coudert B, Maerevoet M, Piot G, Kramar A, Martin AL, Penault-Llorca F

J Clin Oncol. 2009 Dec 20;27(36):6129-34

Prognostic role of pregnancy occurring before or after treatment of early breast cancer patients aged

Largillier R, Savignoni A, Gligorov J, Chollet P, Guilhaume MN, Spielmann M, Luporsi E, Asselain B, Coudert B, Namer M

Cancer. 2009 Nov 15;115(22):5155-65.

Gene expression profile and response to trastuzumab-docetaxel-based treatment in breast carcinoma.

Vegran F, Boidot R, Coudert B, Fumoleau P, Arnould L, Garnier J, Causeret S, Fraise J, Dembele D, Lizard-Nacol S

Br J Cancer. 2009 Oct 20;101(8):1357-64

Circadian rhythm in rest and activity: a biological correlate of quality of life and a predictor of survival in patients with metastatic colorectal cancer.

Innominato PF, Focan C, Gorlia T, Moreau T, Garufi C, Waterhouse J, Giacchetti S, Coudert B, Iacobelli S, Genet D, Tampellini M, Chollet P, Lentz MA, Mormont MC, Levi F, Bjarnason GA

Cancer Res. 2009 Jun 1;69(11):4700-7.

Is immunohistochemistry less sensitive than quantitative reverse transcriptase polymerase chain reaction for hormone receptor status determination in breast cancer?

Arnould L, Coudert B, Fumoleau P

J Clin Oncol. 2009 Jun 1;27(16):2733; author reply 2734-5

Variations in gene expression and response to neoadjuvant chemotherapy in breast carcinoma.

Boidot R, Vegran F, Soubeyrand MS, Fumoleau P, Coudert B, Lizard-Nacol S

Cancer Invest. 2009 Jun;27(5):521-8.

Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study.

Raymond E, Brandes AA, Dittrich C, Fumoleau P, Coudert B, Clement PM, Frenay M, Rampling R, Stupp R, Kros JM, Heinrich MC, Gorlia T, Lacombe D, van den Bent MJ

J Clin Oncol. 2008 Oct 1;26(28):4659-65.

A randomized multicenter study of optimal circadian time of vinorelbine combined with chronomodulated 5-fluorouracil in pretreated metastatic breast cancer patients: EORTC trial 05971.

Coudert B, Focan C, Genet D, Giacchetti S, Cvickovic F, Zambelli A, Fillet G, Chollet P, Amoroso D, Van Der Auwera J, Lentz MA, Marreaud S, Baron B, Gorlia T, Biville F, Levi F

Chronobiol Int. 2008 Sep;25(5):680-96.

Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells.

Ladoire S, Arnould L, Apetoh L, Coudert B, Martin F, Chauffert B, Fumoleau P, Ghiringhelli F

Clin Cancer Res. 2008 Apr 15;14(8):2413-20.

Results of a phase I trial of intravenous vinorelbine plus oral capecitabine as first-line chemotherapy of metastatic breast cancer.

Favier L, Isambert N, Zanetta S, Ferrant E, Mayer F, Chauffert B, Fumoleau P, Garnier J, Biville F, Coudert B

Breast. 2008 Feb;17(1):36-41

[18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy.

Berriolo-Riedinger A, Touzery C, Riedinger JM, Toubeau M, Coudert B, Arnould L, Boichot C, Cochet A, Fumoleau P, Brunotte F

Eur J Nucl Med Mol Imaging. 2007 Dec;34(12):1915-24

Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification.

Arnould L, Arveux P, Couturier J, Gelly-Marty M, Loustalot C, Ettore F, Sagan C, Antoine M, Penault-Llorca F, Vasseur B, Fumoleau P, Coudert BP

Clin Cancer Res. 2007 Nov 1;13(21):6404-9.

Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?

Massard C, Voigt JJ, Laplanche A, Culine S, Lortholary A, Bugat R, Theodore C, Priou F, Kaminsky MC, Lesimple T, Pivot X, Coudert B, Douillard JY, Merrouche Y, Fizazi K

Br J Cancer. 2007 Oct 8;97(7):857-61

Angiogenesis targeting in breast cancer

Fumoleau P, Coudert B, Mayer F, Isambert N, Favier L, Ferrant E

Bull Cancer. 2007;94(7 Suppl):F199-206.

Targeting ErbB receptors in breast cancer

Fumoleau P, Campone M, Coudert B, Mayer F, Favier L, Ferrant E

Bull Cancer. 2007;94(7 Suppl):F147-70.

Cost/effectiveness analysis of adjuvant therapy with trastuzumab in patients with HER2 positive early breast cancer

Fagnani F, Colin X, Arveux P, Coudert B, Misset JL

Bull Cancer. 2007 Jul 1;94(7):711-20.

Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues.

Fumoleau P, Coudert B, Isambert N, Ferrant E

Ann Oncol. 2007 Jul;18 Suppl 5:v9-15.

Diagnostic and predictive value of skin testing in platinum salt hypersensitivity.

Leguy-Seguin V, Jolimoy G, Coudert B, Pernot C, Dalac S, Vabres P, Collet E

J Allergy Clin Immunol. 2007 Mar;119(3):726-30

Feasibility of using intraperitoneal epinephrine and cisplatin in patients with advanced peritoneal carcinomatosis.

Molucon-Chabrot C, Isambert N, Benoit L, Zanetta S, Fraisse J, Guilland JC, Royer B, Monin-Baroille P, Flesch M, Fargeot P, Coudert B, Mayer F, Fumoleau P, Chauffert B

Anticancer Drugs. 2006 Nov;17(10):1211-7.

[Appropriate cytotoxic drug usages in solid tumors: conformity to official labelling and level of scientific evidence]

Grangeasse L, Coudert B, Pivot X, Fumoleau P, Depierre A, Chauffert B, Huichard S, Woronoff-Lemsi MC, Arveux P, Limat S

Bull Cancer. 2006 Oct 1;93(10):1047-54.

Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Can

Giacchetti S, Bjarnason G, Garufi C, Genet D, Iacobelli S, Tampellini M, Smaaland R, Focan C, Coudert B, Humblet Y, Canon JL, Adenis A, Lo Re G, Carvalho C, Schueller J, Anciaux N, Lentz MA, Baron B, Gorlia T, Levi F

J Clin Oncol. 2006 Aug 1;24(22):3562-9.

Sequential addition of an anthracycline-based regimen to docetaxel as neoadjuvant chemotherapy in patients with operable breast cancer.

Amat S, Mouret-Reynier MA, Penault-Llorca F, Leheurteur M, Delva R, Coudert B, Leduc B, Dauplat J, Cure H, Chollet P

Clin Breast Cancer. 2006 Aug;7(3):262-9.

Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?

Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, Cabaret V, Fermeaux V, Bertheau P, Garnier J, Jeannin JF, Coudert B

Br J Cancer. 2006 Jan 30;94(2):259-67.

Sequential two-line strategy for stage IV non-small-cell lung cancer: docetaxel-cisplatin versus vinorelbine-cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: final results of a randomised phase II study.

Douillard JY, Gervais R, Dabouis G, Le Groumellec A, D'Arlhac M, Spaeth D, Coudert B, Caillaud D, Monnier A, Clary C, Maury B, Mornet M, Riviere A, Clouet P, Couteau C

Ann Oncol. 2005 Jan;16(1):81-9.

Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01).

Culine S, Lortholary A, Voigt JJ, Bugat R, Théodore C, Priou F, Kaminsky MC, Lesimple T, Pivot X, Coudert B, Douillard JY, Merrouche Y, Allouache J, Goupil A, Négrier S, Viala J, Petrow P, Bouzy J, Laplanche A, Fizazi K,

J. Clin. Oncol.. 2003 Sep;21(18):3479-82

[Interpretation of the CA125 kinetics during first line chemotherapy of the ovarian cancer: methodological aspects and characteristic profiles]

Riedinger JM, Eche N, Basuyau JP, Daver A, Touzery C, Mayer F, Coudert B, Fargeot P, Chauffert B, de Gislain C, Zanetta S

Ann Biol Clin (Paris). 2002 Mar-Apr;60(2):183-91.

Hepatic arterial infusion of cisplatin diluted in hypotonic 25 g/l glucose solution administered in balloon-occluded hepatic artery: experimental rationale and clinical pilot study.

Isambert N, Correia M, Cercueil JP, Zanetta S, Osmak L, Flesch M, Krause D, Coudert B, Fargeot P, Bedenne L, Chauffert B

J. Exp. Clin. Cancer Res.. 2001 Jun;20(2):183-8

6 cycles of FEC100 vs 6 cycles of epirubicin-docetaxel as neoadjuvant chemotherapy in operable breast cancer patients : preliminary results of a randomized phase II trial of GIREC S01.

Luporsi E, Vanlemmens L, Coudert B

Cancer Conference Highlights 2000;4:2-4.

Dr COUDERT Bruno

Fiche personne

coordonnées

Territoire

Statut

affiliation

équipes/plateformes

Recherche

Projets

Publications